Loading
Life sciences · Journal article
Journal of Drug Targeting · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
:Premature drug release in the systemic circulation or at off-target sites remains a major challenge in conventional drug delivery systems, often resulting in reduced therapeutic efficacy and increased systemic toxicity. Nanotechnology-based delivery platforms have emerged as promising strategies to address these limitations. Among them, mesoporous silica nanoparticles (MSNs) have attracted considerable attention due to their high surface area, tunable pore size, large loading capacity, and considerable structural stability. These features enable efficient encapsulation and controlled delivery of therapeutic cargos. Recent advances in MSN engineering have focused on the development of stimuli-responsive systems capable of releasing drugs in response to specific internal or external triggers, such as pH variations, temperature, light, enzymatic activity, and redox conditions (e.g., glutathione). Such smart nanocarriers facilitate site-specific drug release while minimizing off-target effects. This review highlights recent progress in the design and application of stimuli-responsive MSNs for cancer therapy. Particular emphasis is placed on mechanisms of intracellular uptake, factors influencing cellular internalization, and strategies for controlled drug release. In addition, current insights into the biocompatibility and toxicity of MSNs are discussed to provide a comprehensive perspective on their translational potential in cancer nanomedicine.